{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:27:09Z","timestamp":1789129629320,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctro.2026.101262","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:12:06Z","timestamp":1786979526000},"page":"101262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Post-SABR early PSA density kinetics in androgen deprivation therapy-na\u00efve patients: early landmark models for long-term biochemical recurrence-free survival"],"prefix":"10.1016","volume":"61","author":[{"given":"Carlo","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Pares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasco","family":"Louro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kociolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Simas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Fuks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101262_bb0005","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","article-title":"PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis","volume":"64","author":"Ray","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101262_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110642","article-title":"Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: a scoping review and meta-analysis","volume":"202","author":"Dejonckheere","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0167-8140(98)00061-9","article-title":"The relationship between biochemical failure and time to nadir after external beam radiotherapy for prostate cancer","volume":"48","author":"Aref","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.radonc.2013.03.030","article-title":"Prostate-specific antigen rate of decline post external beam radiotherapy predicts prostate cancer death","volume":"107","author":"Shi","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0025","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdp365","article-title":"Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy","volume":"21","author":"de Crevoisier","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0167-8140(97)00123-0","article-title":"Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer","volume":"44","author":"Zagars","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cncr.20328","article-title":"Early prostate-specific antigen kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model","volume":"101","author":"Cavanaugh","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2026.101262_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0167-8140(94)90040-X","article-title":"The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment","volume":"30","author":"Zagars","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2020.09.053","article-title":"Dose-response with stereotactic body radiotherapy for prostate cancer: a multi-institutional analysis of prostate-specific antigen kinetics and biochemical control","volume":"154","author":"Levin-Epstein","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0050","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ijrobp.2019.06.2539","article-title":"Multi-institutional analysis of prostate-specific antigen kinetics after stereotactic body radiation therapy","volume":"105","author":"Jiang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101262_bb0055","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3109\/0284186X.2014.983656","article-title":"Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer","volume":"54","author":"Kole","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0060","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","article-title":"Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer","volume":"147","author":"Benson","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2026.101262_bb0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10555-019-09815-3","article-title":"Beyond the biomarker role: prostate-specific antigen in the prostate cancer microenvironment","volume":"38","author":"Moradi","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctro.2026.101262_bb0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.radonc.2022.02.016","article-title":"Early PSA density kinetics predicts biochemical and local failure following extreme hypofractionated radiotherapy in intermediate-risk prostate cancer","volume":"169","author":"Greco","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.863655","article-title":"Urethra sparing with target motion mitigation in dose-escalated extreme hypofractionated prostate cancer radiotherapy: 7-year results from a phase II study","volume":"12","author":"Greco","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082180","article-title":"Characteristics of PSA bounce after radiotherapy for prostate cancer: a meta-analysis","volume":"12","author":"Darwis","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101262_bb0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2021.11.005","article-title":"Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: the Phoenix definition and beyond","volume":"166","author":"Ma","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0095","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101262_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctro.2026.101262_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12874-022-01709-3","article-title":"Joint models for dynamic prediction in localised prostate cancer: a literature review","volume":"22","author":"Parr","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ctro.2026.101262_bb0110","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2005.12.156","article-title":"Individualized predictions of disease progression following radiation therapy for prostate cancer","volume":"23","author":"Taylor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101262_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:23:26Z","timestamp":1789125806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":23,"alternative-id":["S2405630826001576"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101262","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-SABR early PSA density kinetics in androgen deprivation therapy-na\u00efve patients: early landmark models for long-term biochemical recurrence-free survival","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101262"}}